New Approved Indication for Ibrutinib

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 6, 2014, págs. 21-22
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Ibrutinib (Imbruvica) has been approved to treat chronic lymphocytic leukemia in patients who've received treatment at least once with other drug therapy.

    * Common adverse effects are numerous and include thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory tract infection, fatigue, musculoskeletal pain, rash, fever, constipation, peripheral edema, arthralgia, nausea, stomatitis, sinusitis, and dizziness.